GUGGENHEIM INVESTMENTS

Aberdeen Medical Science Innovation Portfolio, Series 13

Capitalize on Next-Gen Healthcare Growth Opportunities

Propelled by innovation and changing demographics, the healthcare industry may be entering an age that may offer opportunities to extend and enhance the quality of human lives. In many areas of the healthcare sector, accelerated research, funding, use of technology applications, and faster regulatory approvals are spurring the pace and volume of medical advances and opening new investment opportunities, such as gene therapy, personalized medicine, and cell-based therapies. Guggenheim believes demographic shifts of an aging population and increases in chronic health issues may also act as tailwinds to drive new opportunities in healthcare.

To provide exposure to this exciting growth potential, Guggenheim has partnered with Aberdeen Standard Investments Inc. ("Aberdeen"), to develop the **Aberdeen Medical Science Innovation Portfolio**, which seeks to offer access to innovative medical science companies, companies considered to be developing novel products to address medical needs. Aberdeen has a team of leading healthcare management professionals that combines a top-down perspective based on deep knowledge of the healthcare sector with bottom-up fundamental research to potentially identify some of the most promising opportunities in a dynamic market. The Aberdeen Medical Science Innovation Portfolio seeks to maximize total return by investing in innovative companies that may be able to capitalize from the key trends currently driving healthcare.

Key Themes

The portfolio seeks to offer exposure to ten identified segments of the market where Guggenheim and Aberdeen believe significant innovation and growth are occurring:

Genetic Medicine & Rare Disease

The use of genes to treat rare diseases by inserting functional or healthy copies of a gene to circumvent the function of a mutated gene that is dysfunctional.

Neurological Disorders

Diseases of the brain and central nervous system remain a challenge where current treatment options leave room for improvement. Unmet need exists for those suffering from major depression, migraines, Alzheimer's, and Parkinson's disease.

Biological Discovery

Advancing the understanding of human biology is leading to accelerated demand for instruments, data and suppliers that enable discovery.

Targeted Oncology

Treatments that focus on cancer cells with less harm to normal/healthy cells. A dominant trend is the development of therapies personalized to each individual's specific disease, often using genomic testing.

Autoimmune Disorders

These disorders occur when the immune system mistakenly attacks and damages the body's own cells. New advances are exploring targeted and personalized approaches to treat these disorders.

Advanced Devices & Equipment

Implants, consumables, monitoring equipment and wearables used in the diagnosis and treatment of diseases that may help improve patient outcomes and lowering overall healthcare costs.

Diagnostics

Process of identifying and characterizing disease.

Digital & Personal Health Monitoring

Leverage technology to monitor and manage chronic conditions.

Core Holdings

A health care company Guggenheim and Aberdeen considers to hold a strong competitive position in its area of focus with strong growth opportunities.

Aging Population

The percentage of Americans 65+ is expected to increase 22 percent by 2050[1]—this demographic will likely have more healthcare needs.

Investment Objective

The Aberdeen Medical Science Innovation Portfolio, Series 13 (trust) seeks to maximize total return through capital appreciation.

Key Considerations


- **Growth Potential from Innovation:** Seeks to offer attractive growth opportunities from the advances that may drive the future of the healthcare sector.
- **Portfolio Founded on Healthcare Expertise:** Guggenheim, with the assistance of Aberdeen, selects portfolio holdings through a unique combination of fundamental research and extensive expertise in the healthcare industry.
- **Capitalize on Demographic Trends:** Guggenheim believes an aging population and increases in chronic conditions, such as obesity, diabetes and cancer, may fuel demand for innovative healthcare solutions.

Past performance is no guarantee of future results. There is no guarantee that these trends and projections will continue or come to fruition and they are subject to change.


Portfolio Allocation

Breakdown and weightings are as of 11.17.2026 and subject to change.

CAPITALIZATION BREAKDOWN




STYLE BREAKDOWN



Source: Guggenheim Investments/Aberdeen. **1** Statista, "Share of the U.S. population aged 65 years and older from 1950 to 2050", 2.5.2026.

Security Selection Process

In selecting the innovative healthcare companies to be included in the portfolio, Guggenheim, with the assistance of Aberdeen, starts with a universe of companies in the medical sciences industry, which include healthcare companies, as well as those whose business is involved in researching, developing and producing medical, pharmaceutical or biotechnology products, supplies or equipment.



aberdeen Investments

Aberdeen offers investment expertise across all key asset classes, regions and markets so that clients can capture investment potential wherever it arises. It operates in over 30 locations worldwide, ensuring first-hand insight into companies, industries and markets. As of Sept. 30, 2026, Aberdeen managed $522.4 billion in assets on behalf of individuals, funds, governments, pension funds, insurer, companies, charities and foundations across 80 countries. The combination of Aberdeen's research, thematic thinking, and extensive on-the-ground analysis helps Aberdeen find the most sustainable future-fit investment opportunities globally.

Trends Impacting the Healthcare Industry

# of Clinical Trials by Year

More Than Doubled

In the past 10 years[2]

Impact of Rare Diseases

25M to 30M

Americans affected by rare diseases[3]

Aging Population in U.S.[4]

19.2%	22.8%
2026	Est. 2050

Smart Wearable Health Devices[7]

More Than 1 in 3 U.S. Adults

Use a smart wearable device

Global Overweight & Obesity 2015 – 2030[6]

% of adults (20+) who are overweight or obese

	2015	Est. 2030
Women	40%	50%
Men	39%	50%

Annual U.S. Healthcare Spending[5]

$5.3T	$8.1T
2024	Est. 2032

Projected U.S. Market Growth

$31.7B	$160.4B
2026	Est. 2035

2 Clinicaltrials.gov 233,102 in 2016 to 609,551 in 2026 as of 10.30.2026. **3** The World Data, "Rare Diseases Statistics in U.S. in 2026 | Key Facts," 2.12.2026. **4** Statista, "Share of the U.S. population aged 65 years and older from 1950 to 2050", 2.5.2026. **5** CMS.gov, "National Health Expenditures Projections 2025-2034," June 2026. **6** World Obesity, "World Obesity Atlas 2025 - Overweight, obesity and non-communicable diseases, " March 2025. **7** Towards Healthcare, "U.S. Smart Wearables Market Demand, Size and Growth Rate Forecast 2035," 7.20.2026.

There is no guarantee that the trends and projections noted above will continue or come to fruition and they are subject to change.

Portfolio Holdings

Holdings, breakdown, and weightings are as of 11.17.2026 and subject to change.

Ticker	Name
Advanced Devices and Equipment 11.56%	
BLLN	Billiontoone, Inc.
CSTL	Castle Biosciences, Inc.
DHR	Danaher Corporation
EW	Edwards Lifesciences Corporation
SYK	Stryker Corporation
TNDM	Tandem Diabetes Care, Inc.
WAT	Waters Corporation
Aging Population 14.93%	
ELV	Elevance Health, Inc.
HROW	Harrow, Inc.
HUM	Humana, Inc.
MCK	McKesson Corporation
MOH	Molina Healthcare, Inc.
NAMS	Newamsterdam Pharma Company NV
THC	Tenet Healthcare Corporation
UNH	UnitedHealth Group, Inc.
ZBH	Zimmer Biomet Holdings, Inc.
AutoImmune Disorders 9.96%	
ABBV	AbbVie, Inc.
ARQT	Arcutis Biotherapeutics, Inc.
SPRY	ARS Pharmaceuticals, Inc.
ORKA	Oruka Therapeutics, Inc.
SGMT	Sagimet Biosciences, Inc.
TARS	Tarsus Pharmaceuticals, Inc.
Biological Discovery 10.05%	
TXG	10X Genomics, Inc.
TKNO	Alpha Teknova, Inc.
DOCS	Doximity, Inc.
RGEN	Repligen Corporation
TEM	Tempus AI, Inc.
TMO	Thermo Fisher Scientific, Inc.
Core Holding 6.72%	
ALC	Alcon AG
BMY	Bristol-Myers Squibb Company
ICLR	ICON PLC
PCVX	Vaxcyte, Inc.
Diagnostics 8.38%	
ABT	Abbott Laboratories
GEHC	GE HealthCare Technologies, Inc.
WGS	GeneDx Holdings Corporation
GH	Guardant Health, Inc.
IQV	IQVIA Holdings, Inc.
Digital and Personal Health Monitoring 3.33%	
BSX	Boston Scientific Corporation
DXCM	Dexcom, Inc.
Genetic Medicine & Rare Disease 11.68%	
ARWR	Arrowhead Pharmaceuticals, Inc.
BBIO	Bridgebio Pharma, Inc.
IRON	Disc Medicine, Inc.
OCS	Oculis Holding AG
PVLA	Palvella Therapeutics, Inc.
RLAY	Relay Therapeutics, Inc.
TECX	Tectonic Therapeutic, Inc.
Neurological Disorders 11.74%	
ACHC	Acadia Healthcare Company, Inc.
ALKS	Alkermes PLC
AXSM	Axsome Therapeutics, Inc.
DNLI	Denali Therapeutics, Inc.
JAZZ	Jazz Pharmaceuticals PLC
NPCE	NeuroPace, Inc.
PRAX	Praxis Precision Medicines, Inc.
Targeted Oncology 11.65%	
RCUS	Arcus Biosciences, Inc.
AZN	AstraZeneca PLC
COGT	Cogent Biosciences, Inc.
GMAB	Genmab A/S
IDYA	Ideaya Biosciences, Inc.
MRK	Merck & Company, Inc.
RVMD	Revolution Medicines, Inc.

PORTFOLIO SUMMARY

Inception Date	11.18.2026
Termination Date	11.15.2028
Initial Offer Price	$10.00
Number of Issues	60
Historical Annual Dividend Distribution[8]	$0.0012
Distributions	25th day of each month commencing on 12.25.2026, if any

SALES CHARGES AND ESTIMATED EXPENSES

The sales charges (S/C) and estimated expenses are based on a $10 per unit offering price.

	Standard	Fee/Wrap[9]
Deferred S/C[10]	2.25%	-
Creation and Development (C&D) Fee	0.50%	0.50%
Total S/C	2.75%	0.50%
Estimated Organization Expenses[11]	0.64%	0.64%
Estimated Annual Fund Operating Expenses[12]	0.32%	0.32%

TICKETING INFORMATION - CUSIPS

Cash	40178W143
Reinvest	40178W150
Fee/Cash	40178W168
Fee/Reinvest	40178W176
Ticker	CTMEMX

8 The Historical Annual Dividend Distribution (HADD) is as of the day prior to trust deposit and subject to change. There is no guarantee the issuers of the securities included in the Trust will declare dividends or distributions in the future. The HADD of the securities included in the Trust is for illustrative purposes only and is not indicative of the Trust's distribution rate. The HADD is the weighted average of the trailing twelve-month distributions paid by the securities included in the portfolio, adjusted to reflect corporate actions (such as stock splits), if applicable, and is reduced to account for the effects of fees and expenses, which will be incurred when investing in the Trust. The HADD will vary due to certain factors that may include, but are not limited to, a change in the dividends paid by issuers, a change in Trust expenses or the sale or maturity of securities in the portfolio. **9** Fee/Wrap-based accounts will not be assessed the deferred sales charge for eligible purchases and must purchase units with a Fee-based CUSIP. For unit prices other than $10, percentage of the C&D fee will vary. **10** The deferred sales charge (DSC) is a fixed amount and will be deducted in monthly installments on the last business day commencing June 2027 and ending August 2027 or upon early redemption. For unit prices other than $10, percentages of C&D fees, and DSCs will vary but in no event will the maximum sales charge (S.C) exceed the total S.C. Early redemption of units will still cause payment of the DSC. However, an initial sales charge, which is equal to the difference between the maximum S.C and the sum of any remaining deferred S.C charges and C&D, will be charged if the price paid for units exceeds $10 per unit or you purchase units after the first DSC payment has been assessed. **11** Estimated Organization Expenses are assessed on a fixed dollar amount per unit basis, therefore, actual organization costs may be more or less than estimates. For additional information on organizational costs and potential caps, please see the prospectus. **12** Trust operating expenses include fees for administration, bookkeeping, the trustee, sponsor, and evaluator. This expense also includes an estimated Trust operating expense based upon an estimated trust size. If the Trust does not reach or falls below the estimated size, the actual amount of the operating expenses may exceed the amount reflected. Please see "Fees and Expenses" in the Trusts prospectus for additional information.

Aberdeen Medical Science Innovation Portfolio, Series 13 is a Unit Investment Trust.

RISK CONSIDERATIONS: As with all investments, you may lose some or all of your investment in the trust. No assurance can be given that the trust's investment objective will be achieved. The trust also might not perform as well as you expect. This can happen for reasons such as these: • Securities prices can be volatile. The value of your investment may fall over time. Market values of the Trust's securities fluctuate in response to various factors affecting an issuer. Events such as war, terrorism, natural and environmental disasters, public health emergencies are impossible to predict and may adversely affect the economy, which may negatively impact the performance of the Trust and the Trust's ability to achieve its investment objectives. • The Trust is concentrated in the health care sector. The factors that impact the health care sector will likely have a greater effect on this Trust than on a more broadly diversified trust. • The Trust invests in U.S.-listed foreign securities and in an American Depositary Receipt ("ADR"), which will be more volatile than U.S. securities due to such factors as adverse economic, currency, political, social or regulatory developments in a country. • The Trust invests in securities issued by small- and mid-capitalization companies, which involve more investment risk to limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments. • The Trust may be susceptible to potential risks through breaches in cybersecurity. • The Trust is subject to risks arising from various operational factors and their service providers. Although the Trust seeks to reduce operational risks through controls and procedures, there is no way to completely protect against such risks. **Please see the Trust prospectus for more complete risk information.**

Unit Investment Trusts are fixed, not actively managed and should be considered as part of a long-term strategy. Investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. UITs are subject to annual fund operating expenses in addition to the sales charge. Investors should consult an attorney or tax advisor regarding tax consequences associated with an investment from one series to the next, if available, and with the purchase or sale of units. Guggenheim Funds Distributors, LLC does not offer tax advice.

This material is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation.

Read the trust's prospectus carefully before investing. It contains the trust's investment objectives, risks, charges, expenses and other information, which should be considered carefully before investing. Obtain a prospectus at GuggenheimInvestments.com.

Guggenheim Funds Distributors, LLC

Member FINRA/SIPC

11/2026 UIT-FCT-TMED-013 #6117673